ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

ATON APPOINTS HADRIEN LANVIN AS DEPUTY CEO

Illkirch, February 18, 2026 – 6.30 pm

 

Aton Group (Euronext Growth Paris - FR0004153930 - ALTAO), a leader in life sciences and medical technology, today announced the appointment of Hadrien Lanvin as Deputy Chief Executive Officer.

Alumnus of HEC Paris, Hadrien Lanvin is the Founder and CEO of biotechnology firm Evora Biosciences. Having served on Aton's Board of Directors since December 2023, he brings an intimate knowledge of the Group's portfolio and market dynamics. His track record is defined by his expertise in structuring, scaling, and driving value for high-potential scientific assets.

In his new executive role, Mr. Lanvin will focus on maximizing the valuation of Aton's asset portfolio. He will be responsible for sharpening the Group's strategic positioning, clarifying its growth prospects, and working closely with subsidiary leadership to accelerate their development. A key priority will be increasing the Group's footprint and visibility across both the financial and industrial ecosystems.

"Hadrien's appointment significantly strengthens our leadership team at a pivotal moment in Aton's growth. His deep understanding of our assets and the biotech landscape will be a major catalyst in driving valuation and streamlining our engagement with the investment community, ensuring continuity in our corporate governance." stated Léone Atayi, Chairwoman and CEO of Aton Group.

This evolution of the executive team marks a key milestone in the execution of Aton's strategic roadmap and reinforces its commitment to transparent, high-impact communication with the financial community.

 

Upcoming News

Our next update will provide an operational briefing on Inoviem Scientific, focusing on its latest milestones in translational preclinical research.

 


About Aton
Aton is a medical sciences group dedicated to shaping the future of medicine by improving patient care and treatment efficacy. Aton scales and manages a portfolio of pioneering companies, leveraging their unique synergies to deliver the healthcare solutions of tomorrow.

For more information, visit: www.aton-group.com.

Aton is listed on Euronext Growth (Paris).
ISIN: FR0004153930 – Ticker: ALTAO –Eligibility for PEA and PEA PME-ETI saving schemes

ATON
Léone ATAYI
Chairwoman and CEO
shareholder@aton-group.com


This publication embed "🔒 Actusnews SECURITY MASTER".
- SECURITY MASTER Key: nXBxacZmZWqayXFxaJtraJRna5pllmHKZ2aZm5Vrlp7Hbm9gnWaXmMebZnJnm2pm
- Check this key: https://www.security-master-key.com.



Regulated information:
Inside Information:
- other releases


Full and original press release in PDF: https://www.actusnews.com/news/96650-aton_pr_nomination-hadrien-lanvin_18022026_en-vdef.pdf

Receive by email the next press releases of the company by registering on www.actusnews.com, it's free

Recent Quotes

View More
Symbol Price Change (%)
AMZN  210.11
+5.25 (2.56%)
AAPL  264.58
+4.00 (1.54%)
AMD  200.15
-3.22 (-1.58%)
BAC  53.06
+0.29 (0.55%)
GOOG  314.90
+11.34 (3.74%)
META  655.66
+10.88 (1.69%)
MSFT  397.23
-1.23 (-0.31%)
NVDA  189.82
+1.92 (1.02%)
ORCL  148.08
-8.46 (-5.40%)
TSLA  411.82
+0.11 (0.03%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.